טוען...

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasome activities, and mechanisms of action. Here, we demonstrate that com...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Chauhan, Dharminder, Singh, Ajita, Brahmandam, Mohan, Podar, Klaus, Hideshima, Teru, Richardson, Paul, Munshi, Nikhil, Palladino, Michael A., Anderson, Kenneth C.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2008
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214767/
https://ncbi.nlm.nih.gov/pubmed/18006697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-105601
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!